scholarly journals Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

Cancer ◽  
2008 ◽  
Vol 113 (8) ◽  
pp. 2129-2138 ◽  
Author(s):  
Ali G. Saad ◽  
Beow Y. Yeap ◽  
Frederik B. J. M. Thunnissen ◽  
Geraldine S. Pinkus ◽  
Jack L. Pinkus ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Immunohistochemical Markers ◽  
Nonsmall Cell Lung Carcinoma

Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment

Cancer ◽  
2002 ◽  
Vol 95 (3) ◽  
pp. 605-612 ◽  
Author(s):  
Giovanni Luca Ceresoli ◽  
Michele Reni ◽  
Giuseppe Chiesa ◽  
Angelo Carretta ◽  
Stefano Schipani ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Lung Carcinoma ◽  
Locally Advanced ◽  
Multimodality Treatment ◽  
Cell Lung Carcinoma ◽  
Nonsmall Cell Lung Carcinoma

scholarly journals New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma

2016 ◽  
Vol 46 ◽  
pp. 1854-1861 ◽  
Author(s):  
Ferda BİR ◽  
Duygu ÇELİKER ◽  
Binnaz Fatma EVYAPAN ◽  
Arzu YAREN ◽  
Tamer EDİRNE
Keyword(s):  
Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Immunohistochemical Markers ◽  
Nonsmall Cell Lung Carcinoma

scholarly journals Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Shingo Nakayama ◽  
Mamoru Sasaki ◽  
Shojiroh Morinaga ◽  
Naoto Minematsu
Keyword(s):  
Brain Metastases ◽  
Cell Carcinoma ◽  
Giant Cell ◽  
Tumor Cells ◽  
Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Giant Cell Carcinoma ◽  
Nonsmall Cell Lung Carcinoma ◽  
Programmed Death

Giant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab, an antibody targeting programmed death-1 (PD-1). A 69-year-old woman was diagnosed with NSCLC with multiple brain metastases. Histological evaluation of lung biopsy specimens revealed proliferation of pleomorphic giant tumor cells with poor cohesiveness, findings consistent with giant cell carcinoma. Immunostaining showed that a high proportion of the tumor cells were positive for expression of programmed death-ligand 1 (PD-L1). The patient received stereotactic radiotherapy for the brain metastases, followed by administration of pembrolizumab. Treatment with pembrolizumab resulted in the rapid regression of the primary lung nodule, with the progression-free period maintained for at least four treatment cycles. Immunotherapy targeting PD-1/PD-L1 may be an option for patients with PD-L1-positive NSCLC with giant cell features.

Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors

2005 ◽  
Vol 102 (Special_Supplement) ◽  
pp. 247-254 ◽  
Author(s):  
Jason Sheehan ◽  
Douglas Kondziolka ◽  
John Flickinger ◽  
L. Dade Lunsford
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Content Type ◽  
The Brain ◽  
Fine Print

Object. Lung carcinoma is the leading cause of death from cancer. More than 50% of those with small cell lung cancer develop a brain metastasis. Corticosteroid agents, radiotherapy, and resection have been the mainstays of treatment. Nonetheless, median survival for patients with small cell lung carcinoma metastasis is approximately 4 to 5 months after cranial irradiation. In this study the authors examine the efficacy of gamma knife surgery for treating recurrent small cell lung carcinoma metastases to the brain following tumor growth in patients who have previously undergone radiation therapy, and they evaluate factors affecting survival. Methods. A retrospective review of 27 patients (47 recurrent small cell lung cancer brain metastases) undergoing radiosurgery was performed. Clinical and radiographic data obtained during a 14-year treatment period were collected. Multivariate analysis was utilized to determine significant prognostic factors influencing survival. The overall median survival was 18 months after the diagnosis of brain metastases. In multivariate analysis, factors significantly affecting survival included: 1) tumor volume (p = 0.0042); 2) preoperative Karnofsky Performance Scale score (p = 0.0035); and 3) time between initial lung cancer diagnosis and development of brain metastasis (p = 0.0127). Postradiosurgical imaging of the brain metastases revealed that 62% decreased, 19% remained stable, and 19% eventually increased in size. One patient later underwent a craniotomy and tumor resection for a tumor refractory to radiosurgery and radiation therapy. In three patients new brain metastases were demonstrating on follow-up imaging. Conclusions. Stereotactic radiosurgery for recurrent small cell lung carcinoma metastases provided effective local tumor control in the majority of patients. Early detection of brain metastases, aggressive treatment of systemic disease, and a therapeutic strategy including radiosurgery can extend survival.

scholarly journals Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy

Cancer ◽  
2001 ◽  
Vol 91 (12) ◽  
pp. 2394-2400 ◽  
Author(s):  
F. Andre ◽  
D. Grunenwald ◽  
J. L. Pujol ◽  
P. Girard ◽  
A. Dujon ◽  
...  
Keyword(s):  
Preoperative Chemotherapy ◽  
Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Nonsmall Cell Lung Carcinoma

scholarly journals Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?

Cancer ◽  
1999 ◽  
Vol 85 (2) ◽  
pp. 333-340 ◽  
Author(s):  
James E. Herndon ◽  
Stewart Fleishman ◽  
Alice B. Kornblith ◽  
Michael Kosty ◽  
Mark R. Green ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Nonsmall Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document